Viridian Therapeutics, Inc. (Nasdaq: VRDN) announced today the positive topline data from its Phase 3 clinical trial, REVEAL-1, evaluating elegrobart, a subcutaneously delivered anti-insulin-like growth factor-1 receptor (IGF-1R) antibody, in patients with active thyroid eye disease (TED). The trial met its primary endpoint, demonstrating a statistically significant proptosis responder rate (PRR) of 54% in the Q4W dosing group compared to 18% in the placebo group at week 24. Additionally, the Q8W dosing group achieved a PRR of 63%. The trial also reported a complete resolution of diplopia in 51% of patients treated with elegrobart Q4W versus 16% in the placebo group. Elegrobart was generally well tolerated across both dosing regimens, with low rates of adverse events, particularly hearing impairment. The company ended Q4 2025 with $875 million in cash and anticipates that existing funds, along with potential near-term milestones and anticipated revenues from other products, will support its business plans through profitability. The REVEAL-2 trial, evaluating elegrobart in chronic TED, is on track for topline readout in Q2 2026, with a Biologics License Application (BLA) submission expected in Q1 2027. Viridian will hold a conference call today at 8:00 a.m. ET to discuss these results in detail.

Press Release distribution

National Press Distribution across U.S. Media. Direct Access to Key Decision Making Editors.